Hyperthermia May Stimulate Immune System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 5
Volume 7
Issue 5

BUFFALO, NY--Whole body hy-perthermia, similar to that of a prolonged mild fever, results in antitumor effects that may be due to increased immune system activity and increased induction of heat shock proteins (HSPs). "These proteins are the primary protectors of cells against further heat exposure and other stresses," said John Subjeck, PhD, of Roswell Park Cancer Institute, at the first meeting of the Regional Cancer Center Consortium for Biological Therapy of Cancer, hosted by Roswell Park.

BUFFALO, NY--Whole body hy-perthermia, similar to that of a prolonged mild fever, results in antitumor effects that may be due to increased immune system activity and increased induction of heat shock proteins (HSPs). "These proteins are the primary protectors of cells against further heat exposure and other stresses," said John Subjeck, PhD, of Roswell Park Cancer Institute, at the first meeting of the Regional Cancer Center Consortium for Biological Therapy of Cancer, hosted by Roswell Park.

In murine studies, the Roswell Park researchers have determined that whole body hyperthermia can induce tumor cell apoptosis by simulating the thermal element of a mild fever. This tumor cell killing appears to be due, in large part, to the increased activity of natural killer cells. Dr. Subjeck also presented evidence that tumor vascular and cell adhesion proteins can be affected by this treatment.

"We were somewhat surprised to learn that heat shock proteins could be induced by very mild, low-temperature heat treatments extended for several hours," he said. Observing that this same mild hyperthermia treatment led to alterations in lymphocyte cytoskeleton, uropod formation, and protein kinase C activation and distribution, the researchers began to look more closely at various immune system functions. "We found that all of these biological properties and antitumor effects could be tempered by heat shock protein production," he noted.

Focus on Large Heat Shock Proteins

Current research at Roswell Park is focused on the large-molecular-weight families of HSPs, particularly HSP110 and GRP170, that protect cells from damage by heat, anoxia, and other stresses. HSP110, in particular, has the ability to recognize denatured proteins and help repair them, and probably does so more effectively than any of the other HSPs.

"We are quite excited about these large HSPs because almost nothing is known about their functions, while some of the smaller HSPs have been studied intensively," he noted. A trial is about to begin at Roswell Park that is similar to one underway at M.D. Anderson in the laboratory of Dr. Joan Bull. "We will test the effects of mild hyperthermia on the immune responses and HSP induction in patients with advanced cancer," Dr. Subjeck said. "In the near future, we plan to combine this treatment with other types of cancer immunotherapies."

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content